Moderna, Inc. — Director's Dealing 2020

Apr 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-04-06

Reporting Person: Andres Juan (See remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-06	Common Stock	M	300	$12.21	Acquired	300	Direct
2020-04-06	Common Stock	S	300	$35.13	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-06	Stock Option (Right to Buy)	$12.21	M	300	Disposed	2027-08-29	Common Stock (300)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.08 to $35.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.